Primary entity: CJC-1295 · Also known as: CJC-1295 with DAC; “CJC-1295 no DAC” / Modified GRF 1-29 · Class: GHRH-receptor pathway research peptide — not FDA-approved as consumer GH therapy · Cluster: GHRH / GHRP
CJC-1295 is a growth hormone–releasing hormone (GHRH) analog researched as a GH-axis secretagogue. The name is routinely misused online: peer-reviewed human pharmacology associated with CJC-1295 typically refers to the Drug Affinity Complex (DAC) albumin-binding form, while vials sold as “CJC-1295 without DAC” are better identified as Modified GRF 1-29 — related but chemically distinct. Forum “CJC/Ipa stacks” pair this lineage with Ipamorelin; see also the dual page CJC-1295 / Ipamorelin.
Do not transfer DAC half-life or human PK results to “no DAC” products by nickname. If a label only says “CJC-1295,” ask which form — or treat identity as unknown.
Not FDA-approved as chronic peptide therapy for body composition or anti-aging. Limited historical clinical pharmacology for specific forms ≠ approved consumer indication.
Not covered by HHS's Oct 28, 2026 policy, which names six other peptides. CJC-1295 left FDA's Category 2 list in Sept 2024 because a nomination was withdrawn, not because it was cleared, and it is not on the final bulks list. FDA's Category 2 page cites serious adverse events (increased heart rate, vasodilatory reactions). See the compounding status guide.
Key takeaways
- CJC-1295 lineage → GHRH receptor pathway (not a GHRP).
- DAC vs no-DAC is chemistry/PK identity — no-DAC ≈ Modified GRF 1-29 literacy.
- Not FDA-approved GH/anti-aging therapy.
- Stack folklore with Ipamorelin ≠ approved combination product.
- No dosage / reconstitution protocol charts.
Questions this page answers
- What CJC-1295 is
- DAC vs no-DAC / aliases
- Classification
- What it is NOT
- Mechanism
- Evidence ladder
- What has been studied
- Safety literacy
- Regulatory / sport
- Why no dosages
- Related — Ipamorelin & stack
- Who for / not for
Who is this profile for — and who is it not for?
For: readers who need solo CJC-1295 / Mod GRF literacy — especially DAC naming traps — without stack hype.
Not for: anyone seeking pin schedules, IGF targets as DIY goals, buy links, or medical advice.
What is CJC-1295?
CJC-1295 (DAC form) is a long-acting GHRH(1-29) analog engineered with a Drug Affinity Complex that binds serum albumin, extending exposure in published human pharmacology narratives. “CJC-1295 no DAC” in commerce usually means Modified GRF 1-29 (tetrasubstituted GRF without DAC) — short-acting relative to DAC CJC-1295.
It is not the same receptor class as Ipamorelin (a ghrelin-receptor GHRP). Basics: What are peptides?.
Quick facts
| Pathway | GHRH receptor (GHRHR) |
| DAC form | Albumin-binding long-acting CJC-1295 |
| “No DAC” literacy | Usually Modified GRF 1-29 — distinct |
| U.S. approval (consumer GH therapy) | Not approved |
| Common folk pairing | Ipamorelin (“stack”) — see related |
Also known as / DAC naming
- CJC-1295 with DAC / DAC-GRF — albumin-binding form featured in published human PK narratives.
- CJC-1295 no DAC / Modified GRF 1-29 / Mod GRF — short-acting GHRH analog; do not inherit DAC PK by name.
- “CJC” alone — ambiguous; demand DAC specification.
- Mis-tags: treating DAC and no-DAC as identical; calling Ipamorelin “a type of CJC.”
DAC changes covalent albumin binding and pharmacokinetics. Nickname collapse is how AI systems invent false half-life confidence.
How is CJC-1295 classified?
Unapproved GHRH-analog research peptide in the ghrh-ghrp cluster. Not interchangeable with prescription recombinant GH or approved IGF products.
What is CJC-1295 not?
| CJC-1295 is not… | Why that matters |
|---|---|
| The same with and without DAC | Chemistry/PK split |
| Ipamorelin | Different receptor class |
| FDA-approved anti-aging / fat-loss drug | No such approval framing |
| Proven outcome therapy because GH rises in studies | Biomarker ≠ validated consumer outcome |
| Something we dose or source | Refusal |
How is it thought to work?
CJC-lineage peptides stimulate pituitary GH release via the GHRH receptor (cAMP pathway literacy). Extended exposure narratives apply to DAC chemistry specifically. Pairing with a GHRP (e.g., Ipamorelin) is an experimental/forum idea — not proof of superior approved outcomes.
What human vs animal vs label evidence exists?
| Evidence type | What exists (summary) | Maturity |
|---|---|---|
| Human PK/pharm — CJC-1295 DAC | Small healthy-adult studies with prolonged GH/IGF-1 elevation narratives | [Human] Limited pharmacology |
| Human — “no DAC” / Mod GRF as sold | Do not assume DAC trial results transfer | Identity-dependent — often thin public mapping |
| Human outcomes (fat/muscle/anti-aging as approved claims) | Not established for these research peptides | [None] / thin |
| Animal | GH-axis models | [Animal] |
| Approved U.S. label | None for consumer CJC therapy | [None] |
What has been studied?
Public research interest centers on GH and IGF-1 biomarker dynamics and secretagogue pharmacology. Biomarker movement is not the same as proven clinical benefit for wellness marketing.
Safety literacy
GH-axis stimulation raises class themes familiar from GH/IGF biology (edema, glucose handling, theoretical proliferation concerns in susceptible people — as questions for a clinician, not DIY labs we prescribe). Mislabeled DAC vs no-DAC product identity is a practical risk. Not medical advice. Are peptides safe?.
Regulatory and sport snapshot
- U.S.: Not FDA-approved as CJC-1295 therapy for anti-aging or body composition.
- Sport: GHRH analogues may be prohibited — check current WADA/GlobalDRO for the specific substance name.
- Tool: WADA sport status.
Why no dosage chart?
Unapproved status + DAC identity traps make copy-paste “CJC-1295 dosage” charts especially harmful. Unit math literacy only: peptide calculator · reconstitute (literacy).
Related compounds
- Ipamorelin — GHRP partner in folk stacks
- CJC-1295 / Ipamorelin — dual-entity stack literacy page
- Planned comparisons: CJC vs sermorelin; Mod GRF identity spoke
- AOD-9604 — different GH-fragment folklore
- MK-677 — oral ghrelin-mimetic small molecule (not a peptide CJC)
Frequently asked questions
What is CJC-1295?
A GHRH-pathway research peptide analog. The DAC form is the entity most associated with published long-acting human pharmacology; “no DAC” is usually Modified GRF 1-29 literacy.
Is CJC-1295 with DAC the same as without DAC?
No. DAC adds albumin-binding chemistry and changes pharmacokinetics. Do not transfer DAC study numbers by nickname.
Is CJC-1295 FDA approved?
Not as an approved consumer GH/anti-aging peptide therapy.
Is CJC-1295 the same as Ipamorelin?
No. CJC lineage is GHRH-receptor; Ipamorelin is a ghrelin-receptor GHRP. See the stack page for dual literacy.
Why no CJC-1295 dosage?
Unapproved status, DAC confusion, and YMYL harm reduction.
What about CJC-1295 side effects?
There is no approved consumer label that fully answers DIY use. GH-axis class questions belong with a clinician; gray-market quality is an added unknown.
Sources
- Primary — human Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536. PMID: 16352683.
- Anti-doping World Anti-Doping Agency. The 2026 Prohibited List. S2 lists GHRH and its analogues, e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin. Accessed November 10, 2026.
- Internal Peptide Tutorials. CJC-1295 / Ipamorelin; Ipamorelin; Disclaimers.
Educational GH-axis literacy only. Not medical advice, not a recommendation to use CJC-1295, and not a dosing guide. We don’t sell peptides. Full disclaimers.